🇺🇸 FDA
Pipeline program

BXCL501 80 Micrograms

BXCL501-105

Phase 1 small_molecule active

Quick answer

BXCL501 80 Micrograms for Schizophrenia is a Phase 1 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BioXcel Therapeutics
Indication
Schizophrenia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials